Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.44 |
| ▸ | BACE1 | P56817 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906420 | 0.87 | CNR1 (0.41) | CNR1BACE1 | |
| SCHEMBL4854871 | 0.86 | CNR1 (0.46) | CNR1BACE1 | |
| SCHEMBL4234620 | 0.76 | BACE1 (0.43) | CNR1BACE1KMT2ABACE2MEN1 | |
| SCHEMBL4511383 | 0.75 | KMT2A (0.42) | CNR1BACE1KMT2ABACE2MEN1 | |
| SCHEMBL4519510 | 0.73 | BACE1 (0.44) | BACE1KMT2ABACE2TSHRMEN1 | |
| SCHEMBL4524550 | 0.72 | CNR1 (0.43) | CNR1BACE1 | |
| SCHEMBL4115606 | 0.71 | CNR1 (0.51) | CNR1BACE1 | |
| SCHEMBL20291002 | 0.71 | CNR1 (0.51) | CNR1BACE1 | |
| SCHEMBL4916542 | 0.71 | GAA (0.38) | CNR1BACE1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL4785718 | 0.70 | CNR1 (0.46) | CNR1BACE1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008076046-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076046-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | BACE1, BACE2, PSEN1 | CNR1 1799/4885BACE1 1/4885KMT2A 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.